New data from the CONFIDENCE trial demonstrates that combination therapy with finerenone and empagliflozin leads to ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the and ...

Simultaneous treatment start with finerenone and SGLT-2-inhibitor demonstrated positive data in patients with CKD associated with type 2 diabetes: Berlin Saturday, June 7, 2025, 1 ...

The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of ...

Check the details of medicines, quantity and their prices as notified by the National Pharmaceutical Pricing Authority.

Empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, did not show significant benefit in reducing a first heart failure (HF) hospitalization or death from any cause in patients at ...

LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo. 50% percent of ...

Credit: Getty Images. The approval of empagliflozin for pediatric T2DM was based on data from the phase 3 DINAMO trial. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.